Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin

References

• AdlerAINeilHAManleySE1999Hyperglycemia and hyperinsu-linemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47)Am Heart J138S353S910539797
   PubMed Web of Science ®Google Scholar
• Aim High: Niacin plus statin to prevent vascular eventsClinical trials gov-NCT 00120289
   Google Scholar
• AktoriesKSchultzGJakobsKH1983Islet-activating protein prevents nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase inhibition in rat adipocytesFEBS Lett15688926133780
   PubMed Web of Science ®Google Scholar
• AlvarssonMGrillV1996Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin respondersScand J Clin Lab Invest56563708903118
   PubMed Web of Science ®Google Scholar
• BallantyneCMDavidsonMMcKenneyJ2007Safety and efficacy of a combination of extended-release niacin and simvastatin in patients with dyslipedemia (SEACOAST) – a dose ranging study [abstract]AHA Scientific ConferenceChicago
   Google Scholar
• BaysH2008Safety of niacin and simvastatin combination therapyAm J Cardiol1013818243856
   PubMed Web of Science ®Google Scholar
• ButcherRWBairdCESutherlandEW1968Effects of lipolytic and antilipolytic substances on adenosine 3’, 5’-monophosphate levels in isolated fat cellsJ Biol Chem2431705124384670
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoXQChaitA2001Simvastatin and niacin, anti-oxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med34515839211757504
   PubMed Web of Science ®Google Scholar
• CannerPLBergeKGWengerNK1986Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacinJ Am Coll Cardiol81245553782631
   PubMed Web of Science ®Google Scholar
• ChangAMSmithMJGaleckiAT2006Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistanceJ Clin Endocrinol Metab913303916757523
   PubMed Web of Science ®Google Scholar
• ChengKWuTJWuKK2006Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humansProc Natl Acad Sci U S A1036682716617107
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project Research GroupClofibrate and niacin in coronary heart diseaseJAMA1975231360381
   Google Scholar
• ElamMBHunninghakeDBDavisKB2000Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT [Arterial Disease Multiple Intervention Trial] study. A randomized trialJAMA28412637010979113
   PubMed Web of Science ®Google Scholar
• GanjiSHKamannaVSKashyapML2003Niacin and cholesterol: role in cardiovascular diseaseJ Nutr Biochem1429830512873710
   PubMed Web of Science ®Google Scholar
• GargAGrundySM1990Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitusJAMA26472362374275
   PubMed Web of Science ®Google Scholar
• GibbonsLWGonzalezVGordonN1995The prevalence of side effects with regular and sustained-release nicotinic acidAm J Med99378857573093
   PubMed Web of Science ®Google Scholar
• GinsbergHN2000Insulin resistance and cardiovascular diseaseJ Clin Invest106453810953019
   PubMed Web of Science ®Google Scholar
• GoldbergAAlagonaPJrCapuzziDM2000Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemiaAm J Cardiol851100510781759
   PubMed Web of Science ®Google Scholar
• Grundy2004
   Google Scholar
• GrundySMVegaGLMcGovernME2002Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trialArch Intern Med16215687612123399
   PubMed Web of Science ®Google Scholar
• GuytonJRBlazingMAHagarJ2000Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterolArch Intern Med16011778410789612
   PubMedGoogle Scholar
• GuytonJRBlazingMAHagarJ2000Extended-release niacin versus gemfibrozil for treatment of low levels of high density lipoprotein cholesterolArch Intern Med16011778410789612
   PubMedGoogle Scholar
• GuytonJRGoldbergACKreisbergRA1998Effectiveness of once-nightly dosing of extended release niacin alone and in combination for hypercholesterolemiaAm J Cardiol82737439761083
   PubMed Web of Science ®Google Scholar
• HodisHNMackWJLaBreeL1998The role of carotid arterial intima-media thickness in predicting clinical coronary eventsAnn Intern Med12826299471928
   PubMed Web of Science ®Google Scholar
• Health Protection Study-2-(HPS2-THRIVE). clinicaltrials.gov-00461360.
   Google Scholar
• JinFYKamannaVSKashyapML1999Niacin accelerates intracel-lular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cellsArterioscler Thromb Vasc Biol191051910195935
   PubMed Web of Science ®Google Scholar
• JinFYKamannaVSKashyapML1997Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transportArterioscler Thromb Vasc Biol17202089351367
   PubMed Web of Science ®Google Scholar
• KahnSEBeardJCSchwartzMW1989Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistanceDiabetes3856282653928
   PubMed Web of Science ®Google Scholar
• KasteleinJJP2005The realities of dyslipidaemia: what do the studies tell us?Eur Heart J7Suppl FF27F33
   Web of Science ®Google Scholar
• KarasRHAlSheikh-AliAA2008The safety of niacin in the US Food and Drug Administration Adverse Event Reporting DatabaseAm J Cardiol101103
   Web of Science ®Google Scholar
• KellyJJLawsonJACampbellLV2000Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjectsJ Hum Hypertens145677210980588
   PubMed Web of Science ®Google Scholar
• KnoppRHGinsbergJAlbersJJ1985Contrasting effects of unmodified andtime-release forms of niacin on lipoproteins in hyper-lipidemic subjects: clues to mechanism of action of niacinMetabolism34642503925290
   PubMed Web of Science ®Google Scholar
• KnoppRHAlagonaPDavidsonM1998Equivalent efficacy of a time-release form of niacin (Niaspan) given once a-night versus plain niacin in the management of hyperlipidemiaMetabolism4710971049751239
   PubMed Web of Science ®Google Scholar
• Kos Pharmaceuticals (currently) Abbott Pharmaceuticals DN1628V4-simcor-021408 Prescribing Information 2008.
   Google Scholar
• KraussRM2004Lipids and lipoproteins in patients with type 2 diabetesDiabetes Care27149650415161808
   PubMed Web of Science ®Google Scholar
• LorenzenAStannekCLangHCharacterization of a G protein-coupled receptor for nicotinic acidMol Pharmacol2001593495711160872
   PubMed Web of Science ®Google Scholar
• McGovernME2005Niaspan®: creating a new concept for raising HDL–cholesterolEur Heart J7Suppl FF41F7
   Web of Science ®Google Scholar
• McKenneyJMProctorJDHarrisS1994A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patientsJAMA27167278309029
   PubMed Web of Science ®Google Scholar
• MeyersCDCarrMCParkS2003Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemiaAnn Intern Med139996100214678919
   PubMed Web of Science ®Google Scholar
• MorganJMCapuzziDMGuytonJR1996Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholes-terolemia: a placebo-controlled trialJ Cardiovasc Pharmacol Ther119520210684417
   PubMedGoogle Scholar
• MorrowJDAwadJAOatesJA1992Identification of skinas a major site of prostaglandin D2 release following oral administration of niacin in humansJ Invest Dermatol98812151373750
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP)2002Expert panel on detection (third report), evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final reportCirculation106314342112485966
   PubMed Web of Science ®Google Scholar
• OberwittlerHBaccara-DinetMClinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatmentInt J Clin Pract20066070715
   Google Scholar
• PaoliniJFMitchellYBReyesR2008Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipedemiaAm J Cardiol101625818308010
   PubMed Web of Science ®Google Scholar
• PoyntenAMGanSKKriketosAD2003Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid contentMetabolism5269970412800094
   PubMed Web of Science ®Google Scholar
• RasouliNHaleTKahnSE2005Effects of short-term experimental insulin resistance and family history of diabeteson pancreatic beta-cell function in nondiabetic individualsJ Clin Endocrinol Metab9058253316091496
   PubMed Web of Science ®Google Scholar
• RobinsonJGSmithBMaheshwariN2005Pleiotrophic effects of statins – benefits beyond LDL reduction?J Am Coll Cardiol4618556216286171
   PubMed Web of Science ®Google Scholar
• RubicTTrottmannMLorenzRL2004Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacinBiochem Pharmacol67411915037193
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group1994Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease : Scandinavian Simvastatin Survival Study (4S)Lancet344138397968073
   PubMed Web of Science ®Google Scholar
• SogaTKamoharaMTakasakiJ2003Molecular identification of nicotinic acid receptorBiochem Biophys Res Commun303364912646212
   PubMed Web of Science ®Google Scholar
• SoudijnWvan WijngaardenIIjzermanAP2007Nicotinic acid receptor subtypes and their ligandsMed Res Rev274173317238156
   PubMed Web of Science ®Google Scholar
• SternRHSpenceJDFreemanDJ1991Tolerance to nicotinic acid flushingClin Pharmacol Ther5066701855354
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJ2004Arterial Biology for the Treatment Effects of Reducing Cholesterol 2 (ARBITER 2 Study)Circulation1103512715537681
   PubMed Web of Science ®Google Scholar
• ThoenesMOguchiANagamiaS2007The effects of extended-release niacin on carotid intimal medial thickness, endothelial function, and inflammatory markers in patients with the metabolic syndromeInt J Clin Pract611942817935553
   PubMed Web of Science ®Google Scholar
• TunaruSKeroJSchaubA2003PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effectNat Med9352512563315
   PubMed Web of Science ®Google Scholar
• WangWBasingerANeeseRA2001Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride productionAm J Physiol Endocrinol Metab280E540E711171611
   PubMed Web of Science ®Google Scholar
• WiseAFoordSMFraserNJ2003Molecular identification of high and low affinity receptors for nicotinic acidJ Biol Chem27898697412522134
   PubMed Web of Science ®Google Scholar